readthroughSign in
Jul 31, 2026Weekly roundup

Novo Nordisk registers Korean MASLD/MASH real-world study and semaglutide back pain trial

Two new ClinicalTrials.gov postings cover a Korean observational liver disease study and a Washington University-led semaglutide trial for chronic low back pain.

Novo Nordisk had two studies posted on ClinicalTrials.gov in late July 2026, one as lead sponsor and one as a collaborator.

  • A retrospective observational study sponsored by Novo Nordisk A/S, first posted July 31, 2026, will use existing medical records from adults with MASLD/MASH who underwent two FibroScan-based liver stiffness assessments during routine clinical care in South Korea1. The study is listed as active, not recruiting, with an estimated enrollment of 10000 participants1.
  • A Phase 2 trial testing semaglutide for chronic low back pain, sponsored by Washington University School of Medicine with Novo Nordisk A/S as a collaborator, was first posted July 28, 2026. The trial is not yet recruiting and plans to enroll 250 adults with chronic low back pain and obesity, randomized 1:1 to weekly semaglutide 2.4 mg or placebo for 52 weeks2, with the primary endpoint measured as change in low back pain severity using the 0-10 BPI-SF Pain Severity Scale2.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.